1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61491
Full metadata record
DC FieldValueLanguage
dc.creatorAna Luísa Morais Perdigãopt_BR
dc.creatorRommel Mario Rodríguez Burbanopt_BR
dc.creatorFelipe Paiva Fonsecapt_BR
dc.creatorCarla Isabelly Rodrigues-Fernandespt_BR
dc.creatorGabriela Ribeiro Araújopt_BR
dc.creatorCiro Dantas Soarespt_BR
dc.creatorBruno Augusto Benevenuto de Andradept_BR
dc.creatorManoela Domingues Martinspt_BR
dc.creatorPablo Agustin Vargaspt_BR
dc.creatorHélder Antônio Rebelo Pontespt_BR
dc.creatorFábio Ramôa Pirespt_BR
dc.date.accessioned2023-11-28T21:31:11Z-
dc.date.available2023-11-28T21:31:11Z-
dc.date.issued2021-10-16-
dc.citation.volume16pt_BR
dc.citation.issue2pt_BR
dc.citation.spage476pt_BR
dc.citation.epage485pt_BR
dc.identifier.doihttps://doi.org/10.1007/s12105-021-01387-5pt_BR
dc.identifier.issn19360568pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61491-
dc.description.resumoDiffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS) is the most frequent non-Hodgkin lymphoma subtype. This aggressive neoplasm may variably express the CD30 protein, which may be used as a therapeutic target for this tumor. However, CD30 expression in DLBCL NOS arising from the oral cavity and the oropharynx has not been investigated. Therefore, this study aims to determine the frequency of CD30 expression and its prognostic significance for patients affected by oral/oropharyngeal DLBCL NOS. Fifty cases were retrieved from pathology files and submitted to immunohistochemistry against CD30. Reactivity was accessed by two oral pathologists using two cut-off values (> 0% and > 20% of tumor cells) to determine positivity in each case. Clinical data were obtained from the patients' medical files to investigate the prognostic potential of the protein. Seven high-grade B cell lymphomas and two EBV-positive DLBCL NOS were identified. We found one CD30-positive case in each of these two groups of lymphomas. Among the remaining 41 DLBCL NOS, other four cases (three in the oral cavity and one in the oropharynx) were positive for CD30, but only two expressed the protein in > 20% of tumor cells, both in the oral cavity. Survival analysis demonstrated that CD30-positive cases had a higher five-year overall survival rate (75%) than CD30-negative cases (32.3%), although a statistically significant result was not achieved (p = 0.19). Only a minor subset of oral and oropharyngeal DLBCL NOS express CD30 and these patients seems to have a higher survival rate.pt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofHead and Neck Pathologypt_BR
dc.rightsAcesso Restritopt_BR
dc.subjectacesso restrito springer fao clínica Cd30 expression in oral and oropharyngeal diffuse large b cell lymphoma, not otherwise specified assunto Lymphoma busca dia 09 do 11 2023pt_BR
dc.subjecttítulo periódico Head and neck pathology data 16 outubro ano 2021pt_BR
dc.subject.otherKi-1 antigenpt_BR
dc.subject.otherLymphomapt_BR
dc.subject.otherLymphoma, large B-Cell, diffusept_BR
dc.subject.otherHeadpt_BR
dc.subject.otherNeckpt_BR
dc.subject.otherMouthpt_BR
dc.subject.otherOropharynxpt_BR
dc.subject.otherSurvival ratept_BR
dc.subject.otherImmunohistochemistrypt_BR
dc.titleCD30 expression in oral and oropharyngeal diffuse large b cell lymphoma, not otherwise specifiedpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://link.springer.com/article/10.1007/s12105-021-01387-5pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.